COVID-19: Counseling patients on biologic use
A recently published review offers early insight into the risk and prognosis of COVID-19 in individuals receiving biologic therapy, providing recommendations for patient care and counseling.
A recently published review offers early insight into the risk and prognosis of COVID-19 in individuals receiving biologic therapy, providing recommendations for patient care and counseling.
While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
The new research will compare eblasakimab to dupilumab and lebrikizumab.
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
Review Dermatology Times’ coverage of Rosacea Awareness Month.
Dermatology Times is looking back on the top stories in dermatology from the month of April.
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
Dermatology Times is recapping our top expert interviews from the month of April.